Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices
HRSN
4 other identifiers
observational
144
3 countries
37
Brief Summary
This study evaluates health related social needs screening processes in community oncology clinics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2024
37 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 7, 2024
CompletedFirst Posted
Study publicly available on registry
May 14, 2024
CompletedStudy Start
First participant enrolled
November 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2026
February 19, 2026
February 1, 2026
1.7 years
May 7, 2024
February 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
HRSN screening reach (Part 1)
Determining the perception of the proportion of patients at clinics who are screened for health related social needs (HRSN).
From study enrollment to approximately 4 and 16 weeks post initial study training
Barriers and facilitators influencing HRSN screening implementation
Synthesize themes to create a list of barriers and facilitators influencing HRSN screening implementation within high-implementation clinics, moderate-implementation clinics, and low-implementation clinics.
From study enrollment to time completion of key informant interviews, approximately within 6 months
Generation of a tailored implementation plan for each participating clinic
Generation (defined for each clinic as completed or not completed) of a tailored implementation plan for each participating clinic in Part 3 that includes (1) adaptations to current HRSN screening and follow-up processes, and (2) potential implementation strategies to enhance HRSN screening implementation.
Between time of clinic selection and co-design workshop completion, to be no more than 6 months
Study Arms (3)
Part 1
Part 1: Participants attend training, complete clinic assessments and observations and may complete an interview on study.
Part 2
Part 2: Identified clinic staff will be interviewed to discuss factors that influence health related social needs (HRSN) screening at their clinic and help develop generalized guidance.
Part 3
Part 3: Participants attend a co-design workshop and complete surveys on study feasibility.
Interventions
Eligibility Criteria
NCI Community Oncology Research Program (NCORP) clinics
You may qualify if:
- Part 1
- NCORP PRACTICES:
- Must be an affiliate or sub-affiliate of an NCORP Community or Minority Underserved Community site
- Must provide outpatient oncology care
- Must be a NCORP practice (defined as one or more NCORP affiliates/sub-affiliates, that have a common administrative structure and share providers and/or patients)
- Must have identified two or more Practice Staff that are available and willing to participate on the Practice Interest Form
- Must have identified at least 1-3 outpatient oncology clinics willing to participate on the Practice Interest Form
- CLINICS:
- clinics within the practice should be selected
- Clinics may or may not be located in different physical locations
- The investigators will encourage NCORP practices to select clinics within a practice that differ in current or potential implementation of health related social needs (HRSN) screening (e.g., different clinic workflow or staff, different screening triggers, different tools), so that heterogeneity within NCORP practices can be captured
- Clinics must be willing to allow Practice Staff participants to observe the clinical operations in-person
- PRACTICE STAFF:
- Must be willing and able to take time to observe in person and document 1-3 selected clinics within the practice (approximately 2-3 hours per clinic)
- Must be staff at the selected and enrolled practice. Suggestions of appropriate staff are cancer care delivery research (CCDR) Lead, research nurse, clinical research coordinator or NCORP Administrators. Staff members with primary clinical roles may also be appropriate, if available
- +19 more criteria
You may not qualify if:
- Part 1
- PRACTICE STAFF:
- \*\* Unable to understand, read and communicate in English, as the trainings and observations will be documented in English
- Part 3
- STAFF WORKSHOP PARTICIPANT:
- \*\* Unable to understand, read and communicate in English, as the workshop will be conducted in English
- PATIENT WORKSHOP PARTICIPANT:
- \*\* Unable to understand, read and communicate in English, as the workshop will be conducted in English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (37)
Helen F Graham Cancer Center
Newark, Delaware, 19713, United States
Carle at The Riverfront
Danville, Illinois, 61832, United States
Carle Physician Group-Effingham
Effingham, Illinois, 62401, United States
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938, United States
Carle Cancer Institute Normal
Normal, Illinois, 61761, United States
Illinois CancerCare-Peoria
Peoria, Illinois, 61615, United States
Carle Cancer Center
Urbana, Illinois, 61801, United States
Mission Cancer and Blood - Ankeny
Ankeny, Iowa, 50023, United States
Iowa Methodist Medical Center
Des Moines, Iowa, 50309, United States
Mission Cancer and Blood - Des Moines
Des Moines, Iowa, 50309, United States
University Medical Center New Orleans
New Orleans, Louisiana, 70112, United States
MaineHealth Cancer Care - Brunswick
Brunswick, Maine, 04011, United States
Penobscot Bay Medical Center
Rockport, Maine, 04856, United States
Christiana Care - Union Hospital
Elkton, Maryland, 21921, United States
Cancer Hematology Centers - Flint
Flint, Michigan, 48503, United States
Genesee Hematology Oncology PC
Flint, Michigan, 48503, United States
Genesys Hurley Cancer Institute
Flint, Michigan, 48503, United States
Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota, 56401, United States
Essentia Health Cancer Center
Duluth, Minnesota, 55415, United States
Hennepin County Medical Center
Minneapolis, Minnesota, 55415, United States
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613, United States
CoxHealth South Hospital
Springfield, Missouri, 65807, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, 28374, United States
Wake Forest NCORP Research Base
Winston-Salem, North Carolina, 27157, United States
Essentia Health Cancer Center-South University Clinic
Fargo, North Dakota, 58103, United States
Geisinger Medical Center
Danville, Pennsylvania, 17822, United States
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605, United States
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605, United States
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911, United States
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024, United States
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142, United States
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215, United States
FHP Health Center-Guam
Tamuning, GU, 96913, Guam
Puerto Rico Hematology Oncology Group
Bayamón, 00961, Puerto Rico
Centro Comprensivo de Cancer de UPR
San Juan, 00927, Puerto Rico
San Juan City Hospital
San Juan, 00936, Puerto Rico
MeSH Terms
Conditions
Study Officials
- STUDY CHAIR
Kathryn Weaver, PhD
Wake Forest University Health Sciences
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 7, 2024
First Posted
May 14, 2024
Study Start
November 20, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
November 1, 2026
Last Updated
February 19, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- 6 months after publication for a 2 year duration
- Access Criteria
- upon request to NCORP@wakehealth.edu
Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.